Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz). In January, the FDA approved Omvoh for moderately to severely active Crohn's ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion ...

PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of Age with ...

Eli Lilly (LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to ...

Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of ...

The downsizing of health federal agencies comes after Trump threatened to pull the US out of the World Health Organisation ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...